{"schema_version":"secwatch.filing_event.v1","accession":"0002019410-25-000026","form_type":"8-K","ticker":"CAI","cik":"0002019410","company_name":"Caris Life Sciences, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.328482+00:00","generated_at":"2026-05-17T00:26:00.327944+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Caris Life Sciences Q3 revenue $216.8M, up 113%, raises FY2025 guidance to $720-730M","bullets":["Net income of $24.3M vs. loss of $67.7M YoY; diluted EPS $0.08 vs. ($2.59).","Gross margin expanded to 68.0% from 43.7% YoY; clinical cases up 18.2% to 50,763.","Positive Adjusted EBITDA of $51.2M and free cash flow of $55.3M.","Full-year 2025 revenue guidance raised to $720-730M, representing 75-77% YoY growth.","Molecular profiling services revenue grew 121.3% YoY to $207.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0002019410-25-000026","json":"https://secwatch.observer/filing/0002019410-25-000026.json","markdown":"https://secwatch.observer/filing/0002019410-25-000026.md","text":"https://secwatch.observer/filing/0002019410-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2019410/000201941025000026/0002019410-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2019410/000201941025000026/cai-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:26:00.327944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}